Intriguingly, co-inhibition of adenosine signaling via CD73 and ADORA2A achieved better anti-tumor immune responses compared to single treatments, at least in pre-clinical models of breast and colon cancer (253). This evidence concerns the gene ADORA2A and neoplasm.